LOGIN  |  REGISTER
Assertio
Assertio

AirSculpt Technologies Announces First Quarter Fiscal 2025 Earnings Release Date and Conference Call

April 25, 2025 | Last Trade: US$3.55 0.02 -0.56

MIAMI BEACH, Fla., April 25, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report first quarter 2025 financial results before market open on Friday, May 2, 2025, to be followed by a conference call on the same day at 8:00 a.m. Eastern Time.

The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13753206 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.airsculpt.com. A replay of the webcast will be available for approximately 90 days.

About AirSculpt

AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.

Investor Contact:

Allison Malkin
Partner, ICR Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page